Bausch Health Companies (BHC) Cash & Equivalents (2009 - 2026)

Bausch Health Companies has reported Cash & Equivalents for 18 years, with the latest figure at $1.8 billion in Q2 2026.

• Quarterly Cash & Equivalents rose 5.67% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 5.67% YoY) and the FY2025 annual result came in at $1.3 billion, up 10.84% from the prior year.
• Cash & Equivalents rose to $1.8 billion in Q2 2026 per BHC's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.8 billion in Q2 2026 and troughed at $486.0 million in Q3 2022.
• A 5-year average of $977.3 million and a median of $853.5 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 58.53% in 2023, then jumped 190.25% in 2025.
• Over 5 years, Cash & Equivalents stood at $564.0 million in 2022, then surged by 67.91% to $947.0 million in 2023, then rose by 24.71% to $1.2 billion in 2024, then increased by 10.84% to $1.3 billion in 2025, then jumped by 39.42% to $1.8 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.8 billion, $1.3 billion, and $1.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.